Scientists test 5,000 combinations of 100 existing cancer drugs to find more effective treatments

Scientists in the United States have tested all possible pairings of the 100 cancer drugs approved for use in patients in order to discover whether there are any combinations not tried previously that are effective in certain cancers.

Dr Susan Holbeck (PhD), a biologist in the Division of and Diagnosis at the National Institute (USA) will tell the 24th EORTC-NCI-AACR Symposium on and in Dublin, Ireland, today that she and her colleagues have completed testing the 100 drugs, with 300,000 experiments to test the 5000 possible in a panel of 60 cell lines developed by the (NCI-60 panel). "The goal is to identify combinations that are more active than the single agents alone. Since these are all approved agents, there is the potential to rapidly translate these combinations into the clinic," she will say.

Cancer treatments often use a combination of drugs, as a single rarely produces a long-lasting response due to the cancer becoming drug resistant. Some drug combinations have evolved over time by incorporating new agents into existing standards of care, while many newer treatments try to select combinations of drugs that target particular pathways that are known to be involved in the development of the cancer. However, some combinations can be so toxic that they have to be used at lower doses that may not be effective against the cancer.

"In addition, there are a large number of drug combinations that have never been used together in people, and for which there is no experimental information on whether there might a benefit to the combination," said Dr Holbeck. "We decided that it would be a feasible project to generate experimental data for all 5000 possible combinations of pairs, and that we would make these data available to all to enable additional experiments in support of taking new combinations to .

"In order to provide a resource for understanding the efficacy of drug combinations, we have undertaken a systematic screening of most small molecule oncology drugs approved in the US, each in combination with all the others. This was done using a panel of human tumour cell lines derived from nine different types of cancer.

"We chose to test the combinations in the NCI-60 panel – a group of diverse cell lines that our programme has used for many years to screen potential new drugs – because we have a lot of information about these cell lines. For instance, mutations, gene expression, microRNA expression and so on have all been characterised, and this enables us to analyse the cell lines that benefit from a particular combination and potentially identify markers in those cell lines that might also be used as biomarkers in patients."

The researchers have found that some combinations have shown benefit in many cell lines, while others are active in just a few cell lines. When some of the new combinations were tested in human tumours grafted into mice, they were found to be more effective than the most active doses of single drugs.

"These results are promising but we need to repeat and confirm them," said Dr Holbeck. "Our goal is to rapidly translate several novel combinations into clinical trials. There will be many more leads than we can possibly follow through on. Once these data are published, the dataset, and tools to analyse it, will be made available on our web site for all to utilise as they wish.

"To our knowledge this is the first systematic characterisation of approved drugs in a large number of cancer cell lines. We are not making any assumptions about which combinations will give improved activity. The use of many diverse cancer cell lines allows data mining for markers of response that would not be possible with a small set of cell lines.

"Many groups are focusing on 'rational' combinations, i.e. making scientific inferences about which pathways it might make sense to block simultaneously with different drugs. We took a step back, and took an approach that tests all possible drug pairs. This allowed us to test not only the rational combinations, but also to explore drug pairs that otherwise would likely never be tested together."

Professor Stefan Sleijfer, the scientific chair of the EORTC-NCI-AACR Symposium, from Erasmus University Medical Centre (The Netherlands), commented: "This study is interesting because of the use of combinations of drugs already approved and on the market, which were tested in that have been well characterised in terms of genetic profiles. If confirmed, this study will form a basis for future clinical trials on such combinations in well-defined patient groups."

More information: This work was conducted under contracts from the National Cancer Institute, USA.

Provided by ECCO-the European CanCer Organisation

4.3 /5 (3 votes)
add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Unraveling the 'black ribbon' around lung cancer

Apr 17, 2014

It's not uncommon these days to find a colored ribbon representing a disease. A pink ribbon is well known to signify breast cancer. But what color ribbon does one think of with lung cancer?

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

gdpawel
not rated yet Nov 27, 2012
The application of combination therapy may represent one of the most important applications of the functional cytometric profiling platform, enabling clinicians to explore both anticipated and unanticipated favorable interactions.

Equally important may be the platform's capacity to study drug antagonism wherein two effective drugs counteract each others' benefits. This phenomenon, characterized by the whole being less than the sum of the parts, represents a major pitfall for clinical trialists who simply combine drugs because they can.

These analyses are revolutionizing the way functional cytometric profiling applies newer classes of drugs and has the potential to accelerate drug development and clinical therapeutics. Good outcomes require good drugs, but better outcomes require good combinations. Intelligent combinations are a principle focus of functional cytometric profiling.

http://cancerfocu...p?t=3775